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Psychiatric disorders are one of the leading causes of disability worldwide. Although 
several therapeutic options are available, the exact mechanisms responsible for the 
genesis of these disorders remain to be fully elucidated. In the last decade, a body of 
evidence has supported the involvement of the immune system in the pathophysiology 
of these conditions. Microglial cells play a significant role in maintaining brain homeo-
stasis and surveillance. Dysregulation of microglial functions has been associated with 
several psychiatric conditions. Cannabinoids regulate the brain–immune axis and inhibit 
microglial cell activation. Here, we summarized evidence supporting the hypothesis that 
microglial cells could be a target for cannabinoid influence on psychiatric disorders, such 
as anxiety, depression, schizophrenia, and stress-related disorders.
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inTRODUCTiOn
Microglial Cells and Psychiatric Disorders
Over the last 20 years, both the innate and adaptive components of the immune system have been 
associated with the development of psychiatric disorders, such as depression (1) and schizophrenia 
(2). However, the mechanisms involved in this association are not altogether clear. Although a full 
review of these mechanisms would be out of the scope of this mini-review, recent evidence indicates 
that microglial cells could be important players in this complex puzzle and future targets for the 
treatment of these disorders (3).
Microglial cells are macrophage-like cells involved in immune surveillance of the central nervous 
system (CNS) and are a major source of inflammatory mediators in the brain (4). They originate from 
primitive myeloid progenitors before embryonic day 8 and from infiltrating myeloid cells during 
embryonic and postnatal development (5, 6). Microglia also contributes to CNS homeostasis and 
plasticity by removing redundant synapses and eliminating dying neurons; modulating neurotrans-
mitter release and neurogenesis; and producing neurotrophic factors (7, 8).
During processes that challenge the brain milieu microglial cells proliferate and change their 
morphology from surveillance (ramified form) to executive and phagocytic state (amoeboid form, 
activated microglia) (9). Similar to peripheral macrophages, microglial cells assume at least two 
distinct states of polarization: M1, a profile that secretes proinflammatory cytokines, and M2, a 
pro-resolution state (4). The activated microglia releases proinflammatory mediators that, along with 
its phagocytic activity, may lead to brain damage and contribute to the development of psychiatric 
disorders (4).
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immune System, Microglia, Anxiety, and 
Stress-Related Disorders
Stressful experiences such as social defeat activate long-lasting 
peripheral and central immune response (10–12) and induce 
microglial activation, myelopoiesis in the bone marrow and 
spleen, infiltration of monocytes into the brain and neuroinflam-
mation (12–14).
In humans, posttraumatic stress disorder (PTSD) patients pre-
sent increased peripheral levels of cytokines, in basal and inflam-
matory conditions (15, 16). Also, although no longer classified as an 
anxiety disorder, alterations in the immune system of patients with 
obsessive-compulsive disorder have also been reported (17, 18).
The activation and morphological changes of microglial cells 
associated with neuroinflammatory states have been recently 
found to depend on changes induced by stress, including the 
engagement of glucocorticoids and β-adrenergic receptors (19).
Pharmacological strategies to suppress microglial activity sup-
port the involvement of these cells in the development of disease- 
or stress-induced neuroinflammation and behavioral alterations 
(20–22). Minocycline is a tetracycline-derived antibiotic with 
central anti-inflammatory properties that readily crosses the 
blood–brain barrier (23, 24). It attenuates microglial activa-
tion, neuroinflammation, synaptic plasticity, neurogenesis, and 
behavioral changes in animal models of stress-related disorders 
(19, 22, 25–27) and after systemic lipopolysaccharides (LPSs) 
administration (28, 29). The mechanisms of minocycline anti-
inflammatory effects are not clear, but may involve facilitation of 
endocannabinoid (eCB) signaling, since they can be prevented 
by CB1 or CB2 receptor antagonists (30). However, its effects in 
patients with anxiety disorders are still unknown.
Propranolol, a β-adrenergic receptor antagonist, also attenu-
ates anxiety-like behavior, stress-induced brain proinflammatory 
profile (including infiltration of peripheral macrophages into 
the brain and microglial activation) (31, 32), and the increase in 
bone marrow monocytes progenitors (33). These effects could be 
due to an inhibitory effect on stress-induced peripheral immune 
system activation (12). Anti-inflammatory effects have also been 
described for antidepressant drugs after clinical and preclinical 
studies (34–36).
Overall, these results suggest that modulation of microglial 
proinflammatory profile, either centrally or by interference with 
peripheral sympathetic activity, could induce anxiolytic and 
antistress effects.
immune System, Microglia, and 
Depression
Patients with mood disorders exhibit an activated inflamma-
tory status (37–39), characterized by increases in the number of 
circulating lymphocytes and macrophages and proinflammatory 
cytokines (40). Treatment of inflammatory conditions with 
interferon-α induces depressive symptoms and decreases seroto-
nin levels in the prefrontal cortex of patients (41). These effects 
could be related to central activation of the enzyme indoleamine 
2,3-dioxygenase (IDO) (42, 43). Proinflammatory cytokines are 
proposed to activate IDO that, by interfering with tryptophan/
kynurenine metabolism, decreases serotonin levels and facilitates 
the production of quinolinic acid, an N-methyl-d-aspartate 
(NMDA) receptor agonist (40, 44). Microglial and astrocyte cells 
control IDO activity. Moreover, activated microglia and infiltrated 
macrophages have a high capacity for synthesizing quinolinic acid 
(45). Victims of suicide with the history of affective disorder have 
increased density of activated phagocytes in the ventral prefrontal 
white matter (46) and upregulation of the gene IBA1, associated 
with phenotypic changes in microglia, and MCP-1, a chemokine 
responsible for attracting monocytes, in the dorsal anterior cingu-
late (47, 48). Besides the increased number of activated microglial 
cells are reported in the hippocampus of bipolar patients (49).
Antidepressant drugs are reported to inhibit IL-6 (50, 51) and 
TNF-α production (52). Antidepressants inhibit LPS-stimulated 
microglia (36). Moreover, fluoxetine prevents IκB-α degradation 
and NF-κB nuclear translocation (53), while lithium decreases 
LPS-induced microglial activation through the PI3K/Akt/FoxO1 
signaling pathway (54). Corroborating these findings, studies 
suggest that anti-inflammatory drugs as add-on therapy to anti-
depressant medication may boost depression treatment (55–57).
Stressful experiences are highly associated with predisposition 
for both depression episodes and immune dysfunction (58, 59). 
Stress activates microglia in the prefrontal cortex, amygdala, and 
hippocampus of mice (60) and impairs synaptic plasticity by 
reducing neuronal activity and decreasing dendritic spine den-
sity (61). The high levels of proinflammatory cytokines secreted 
by microglia downregulate neurotrophic factors, intracellular 
growth pathways, and neurogenesis (61, 62), in which mecha-
nisms believe to be downregulated in depressive states.
immune System, Microglia, and 
Schizophrenia
Increased expression of inflammatory markers in blood and brain 
tissues (63–65) and changes in genes that control the expression 
of immune system components have been described in schizo-
phrenia patients (66). Prenatal exposure to inflammatory agents 
increases the risk for schizophrenia development (67) and meta-
analyses indicate the potential use of anti-inflammatory drugs as 
adjunct treatment in schizophrenia (68).
Postmortem brains of schizophrenia patients present activa-
tion and increased cellular density of microglia (69–71). The lat-
ter finding has been confirmed by positron emission tomography 
studies using in  vivo markers of activated microglia (72–74). 
Additionally, elevated microglial activity is also observed in peo-
ple at ultra high risk of psychosis and is associated with symptom 
severity, suggesting a link between microglial activation and the 
risk of psychosis (74). Increased microglial activation is also 
observed in animal models of schizophrenia (75, 76). Although 
it is unclear how changes in microglial activity result in schizo-
phrenia symptoms, there seems to be an association between 
microglial activation and negative and cognitive symptoms (77, 
78). In line with this proposition, minocycline improved nega-
tive symptoms and cognitive function as an add-on treatment in 
schizophrenia patients (77, 79, 80). Antipsychotic-like effects of 
minocycline have also been observed in preclinical studies (81, 
82). Together, these results suggest that inhibition of microglial 
activation may improve schizophrenia symptoms.
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CAnnABinOiDS AS 
iMMUnOMODULATORS in THe CenTRAL 
neRvOUS SYSTeM
The eCB system was initially described in the late 1980s after the 
identification of specific receptors (83). It now comprises the can-
nabinoid receptor types 1 (CB1) and 2 (CB2), their endogenous 
ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), 
and the enzymes responsible for their synthesis and degradation 
(84–86).
In the CNS, eCBs modulate synaptic function and act as a 
homeostatic mechanism on HPA axis (87). During stressful or 
threatening situations, eCBs favor HPA axis activation through 
the amygdala. Glucocorticoids, by enhancing the production of 
eCB, modulate glutamatergic and GABAergic neurotransmission 
via CB1 receptors (87). These receptors are highly expressed 
in presynaptic terminals and their activation suppresses the 
release of several neurotransmitters, such as glutamate, GABA, 
and serotonin (88). CB1 is also expressed in astrocytes (89), 
oligodendrocytes (90), and neural precursor cells, which also 
expresses CB2 receptors (91). In addition to CB1, CB2 receptors 
are constitutively expressed in microglia cells (92) and its expres-
sion increases in inflammatory conditions (93). These receptors 
have been proposed as key regulators of the immune functions, 
including microglial activation (94–96). They are overexpressed 
during neurodegenerative diseases, such as Alzheimer’s disease 
and multiple sclerosis, conditions in which activated microglia 
is observed (97). Recently, Mecha et al. (98) demonstrate that the 
eCB system, by activating CB2 receptors, not only influences the 
migration, proliferation, and release of proinflammatory media-
tors of microglial cells but also affects their phagocytic function 
and drive these glial cells to the M2 state.
2-Arachidonoylglycerol can protect neurons exposed to 
harmful insults by acting as an endogenous inhibitor of cyclooxy-
genase-2 (COX-2) (99), whereas AEA inhibits TNF-α-induced 
NF-κB activation by direct inhibition of the IκB kinase (100). 
Pharmacological inhibition of AEA hydrolysis reduces microglial 
activation, nitric oxide levels, and the production of inflamma-
tory mediators (101). Under pathological conditions, microglia 
cells produce large amounts of eCBs, which could facilitate an 
anti-inflammatory phenotype of microglia (92). Enzymes con-
trolling eCB tone also plays an important neuroprotective role 
during neuroinflammatory process (97). Supporting the involve-
ment of eCBs in immune modulation, the neuroprotective effect 
and inhibition of microglial activation induced by minocycline 
were prevented by CB1 and CB2 receptor antagonists in a rodent 
model of traumatic brain injury (30).
Exogenous cannabinoids can also modulate microglia activa-
tion (97, 102, 103). They reduce the binding of transcription factors 
to CRE and NF-κB in immune cells (104) and inhibit cytokine and 
chemokine production (105). WIN55,212-2, a mixed CB1/CB2 
receptor agonist, reduced brain mRNA expression of proinflam-
matory cytokines, such as TNF-α and IL-6, in a viral model of 
multiple sclerosis (106) and in the Alzheimer’s disease model 
of Aβ amyloid injection (107, 108). Moreover, WIN55,212-2 
also decreased the number of activated microglia related to Aβ 
administration (107) or the aging process in rats (102).
Cannabinoids, Microglia, and Anxiety 
Disorder
Overexpression of CB1 and CB2 receptors, or their acute 
pharmacological activation, promotes anxiolytic-like effects 
(109, 110), whereas their genetic deletion or pharmacological 
blockade causes opposite results (111, 112). These receptors also 
attenuate the increased proinflammatory profile observed in the 
frontal cortex after subchronic stress in mice (113, 114), reducing 
microglial activation and proliferation (95, 115–117).
Cannabinoids could also attenuate anxiety by modulating 
the release of IL-1ra, the endogenous antagonist of IL-1β, by 
glial cells in response to glutamate (118), and by interfering with 
the HPA axis (119). In the latter case, glucocorticoids modulate 
microglial activation induced by stressors (120, 121) and suppress 
hippocampal and amygdala eCB signaling (122).
Cannabinoids, Microglia, and Depression
Lipopolysaccharide induces “sickness behavior” in rodents, a syn-
drome that shows some similarity with depressive symptoms and 
depends on prolonged cytokines release and microglial activation 
(123, 124). Accordingly, using LPS as inflammatory stimulus, 
cannabinoids reduced the number of circulating lymphocyte, 
corticosterone levels (125), and the release of IL-1β, TNF-α, 
and iNOS expression in vitro (126). Moreover, the long-lasting 
behavioral deficits induced by LPS are prevented by the admin-
istration of THC (127) or cannabidiol (CBD) (108). As discussed 
above, in addition to interfere with HPA axis (119), cannabinoids 
can directly decrease microglial activation and attenuate stress-
induced neuroinflammatory states (108, 125, 126).
Although the specific contribution of CB1 and CB2 receptors 
for the aforementioned anti-inflammatory effects is still unclear, 
the neuroprotective effects of CB2 agonists are associated with a 
decrease in the number of activated microglial cells (107). In vitro 
studies indicate that these receptors, located at microglial cells, 
facilitate the production of anti-inflammatory mediators (128). 
Considering the pieces of evidence suggesting that depression 
could be a “microglial disease,” these results point to CB2 recep-
tors located at this cells as possible targets for future antidepres-
sant treatments.
Cannabinoids, Microglia, and 
Schizophrenia
Adolescent cannabis exposure represents a risk factor for devel-
oping schizophrenia later in life (129). Besides the long-lasting 
changes in neuronal activity induced by adolescent cannabinoid 
exposure (76, 130), increased microglial activation in the pre-
frontal cortex (131) and hippocampus of adult rats have also been 
observed (132). Moreover, ibudilast (AV411), a non-selective 
phosphodiesterase inhibitor that suppresses glial cell activation 
(133), prevents the development of behavioral changes induced 
by adolescent THC exposure (131).
Unlike THC, CBD is a phytocannabinoid devoid of psychoto-
mimetic activity that present antipsychotic activity (134). The 
mechanism of action involved in this effect is not entirely under-
stood. However, the anti-inflammatory and neuroprotective 
effects of this drug (135) may contribute to its beneficial effects in 
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schizophrenia. Repeated treatment with CBD-attenuated behav-
ioral deficits and the percentage of Iba-1-positive microglial cells 
with a reactive phenotype in the medial prefrontal cortex and 
dorsal hippocampus of mice chronically treated with the NMDA 
receptor antagonist MK-801 (136). CBD treatment also attenu-
ated the decreased number of GABAergic parvalbumin-positive 
cells in the medial prefrontal cortex, which could, by reducing 
inhibitory tonus in this region, facilitate glutamate release and 
lead to microglial activation (137). Interestingly, schizophrenia 
patients with a higher inflammatory state had more deficits in 
GABAergic neuron-related mRNAs, including GAD67 and 
parvalbumin (138).
Regarding the eCB system, whereas higher levels of 2-AG 
have been observed in the prefrontal cortex, hippocampus, 
and cerebellum of schizophrenia patients, AEA levels are lower 
(139). Moreover, increased AEA levels in the cerebrospinal fluid 
correlate negatively with psychotic symptoms (140) and the 
antipsychotic effect of CBD was associated with increased AEA 
serum levels. This latter effect likely reflects CBD inhibition of the 
FAAH enzyme, responsible for AEA degradation (141). Increases 
in eCBs may contribute to defense mechanisms through accu-
mulation of anti-inflammatory microglia phenotype (92). Thus, 
the pharmacological inhibition of eCB hydrolysis may be a useful 
approach in the schizophrenia treatment.
As aforementioned, CB2 receptors are expressed on microglia 
and its expression is strongly upregulated when these cells are 
activated. Schizophrenia has been associated with single nucleo-
tide polymorphisms in the CB2 receptor gene that reduce its 
expression and functionality (142). Decreased expression of CB2 
receptors in isolated peripheral blood mononuclear cells is found 
during first-episode psychosis (143). However, no study has 
evaluated changes on CB2 receptor expression in microglia cells 
in the brain of schizophrenia patients. In rodents, pharmacologi-
cal or genetic CB2 receptor blockade increases susceptibility for 
developing schizophrenia-like symptoms (111, 142). Additionally, 
a CB2 receptor agonist reversed sensorimotor gating deficits in 
mice induced by MK-801 (144). However, the involvement of 
microglial CB2 receptors in these effects is unknown.
COnCLUSiOn
A large body of evidence supports the involvement of neuroin-
flammatory mechanisms, including microglial activation, in the 
pathophysiology of psychiatric disorders. Drugs that interfere 
with these mechanisms, such as cannabinoids, could be a novel 
and important new pathway for the treatment of these disorders 
(Figure 1). Despite these pieces of evidence, few studies have yet 
directly investigated if interference with microglial cell activation 
is essential for the therapeutic effects of cannabinoids in psychi-
atric disorders. Additional studies, therefore, are needed to test 
this hypothesis.
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FiGURe 1 | The inflammatory status observed in patients with psychiatric disorders might lead to activated microglia and neuronal/synaptic 
damage. Activation of cannabinoids receptors (mainly CB2 in activated microglia) by (endo)cannabinoids would drive microglia to a M2 (pro-resolution) state, 
decreasing the production of proinflammatory mediators and protecting neurons from damage.
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